Skip to main content
NanoVibronix, Inc. logo

NanoVibronix, Inc. — Investor Relations & Filings

Ticker · NAOV ISIN · US63008J7028 LEI · 5493008114LTFZQ2I595 US Manufacturing
Open in API
Filings indexed 512 across all filing types
Latest filing 2020-08-24 Capital/Financing Update
Country US United States of America
Listing US NAOV

About NanoVibronix, Inc.

https://nanovibronix.com/

NanoVibronix, Inc. is a medical technology company that develops non-invasive and minimally invasive biological response-activating devices. The company's core technology is based on a proprietary, patented low-intensity surface acoustic wave (SAW) ultrasound. Its main products include PainShield®, a portable device for pain therapy and the treatment of nerve and soft tissue damage, and UroShield®, an ultrasound device designed to prevent bacterial biofilm on urinary catheters. These prescription-based products offer therapeutic alternatives to medication for pain management, wound healing, and biofilm prevention, targeting both clinical and home care settings.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a $2.5 million bought deal offering by NanoVibronix, Inc. It details the underwriting agreement, share price, number of shares, use of proceeds, and related information about the offering. The document references a Registration Statement and a Preliminary Prospectus Supplement but does not contain financial statements or detailed financial analysis. It is primarily an update on a capital raising event, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback.
2020-08-24 English
10-Q/A Filing
Interim / Quarterly Report Q2 2020
2020-08-24 English
424B5 Filing
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by NanoVibronix, Inc. It includes detailed information about the offering of common stock, underwriting, risk factors, use of proceeds, and other related disclosures. The document is part of a registration statement filed with the SEC and is clearly a capital raising document. It is not a financial report, earnings release, management discussion, or any other type of report but rather a detailed offering prospectus supplement. Therefore, it fits the category of Capital/Financing Update (CAP).
2020-08-24 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q2 2020
2020-08-19 English
D Filing
Regulatory Filings
2020-08-18 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing with the SEC. It specifically states that the company, NanoVibronix, Inc., was unable to file its Quarterly Report on Form 10-Q for the period ended June 30, 2020, on time due to COVID-19 related delays. The document explains the reasons for the delay and states the company expects to file the report within the extension period allowed. There are no actual financial statements or substantive financial data included in this document; it is purely a notification about the late filing of a 10-Q report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is an officer certification/notification about a filing delay rather than the report itself.
2020-08-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.